RxDoctor Payments Data

Lena Villanueva

Nurse Practitioner · Norfolk, VANPI 1912617812

Payments from drug & device makers

$1,165in general payments, 2019–2025

Across 24 payments — averaging $48.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$485
  • Neurocrine Biosciences, Inc.$252
  • Axsome Therapeutics, Inc.$124
  • Otsuka America Pharmaceutical, Inc.$124
  • Eisai Inc.$96
  • Johnson & Johnson$66
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$1,165100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,165 in reported general payments places this provider in the 85th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$53,923
Medicare patients
152
Services billed
576

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate40$218,916
Invega SustennaPaliperidone Palmitate44$156,455
RexultiBrexpiprazole35$25,107
Quetiapine Fumarate ErQuetiapine Fumarate38$10,878
NuedextaDextromethorphan Hbr/Quinidine15$9,087
Aripiprazole37$8,214
Buspirone Hcl262$7,034
Memantine Hcl121$6,758
Sertraline Hcl178$5,113
Lurasidone Hcl16$5,025
Duloxetine Hcl158$4,656
Paliperidone ErPaliperidone26$4,131
Divalproex Sodium ErDivalproex Sodium58$3,742
Oxcarbazepine56$3,355
Trazodone Hcl167$2,902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$252$218,91640 claims
Johnson & JohnsonInvega Sustenna$66$156,45544 claims
Otsuka America Pharmaceutical, Inc.Rexulti$124$25,10735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →